Postinjury fibrinolysis shutdown: Rationale for selective tranexamic acid

Journal of Trauma and Acute Care Surgery

Volumn 78, Issue 6, 2015, Pages S65-S69

  Moore, Ernest E ^a   Moore, Hunter B ^a   Gonzalez, Eduardo ^a   Chapman, Michael P ^a   Hansen, Kirk C ^a   Sauaia, Angela ^a   Silliman, Christopher C ^b,c   Banerjee, Anirban ^a  

^a DENVER HEALTH MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Bonfils Blood Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; TRANEXAMIC ACID; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

BATTLE INJURY; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; BLUNT TRAUMA; CONFERENCE PAPER; FIBRINOLYSIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; BLOOD COMPONENT THERAPY; INJURY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANTIFIBRINOLYTIC AGENTS; BLOOD COMPONENT TRANSFUSION; FIBRINOLYSIN; FIBRINOLYSIS; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANEXAMIC ACID; WOUNDS AND INJURIES;

EID: 84964697972     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0000000000000634     Document Type: Conference Paper

References (33)

1. Macfarlane RG, Biggs R. Fibrinolysis: its mechanism and significance. Blood. 1948;3:1167-1187.
2. Sherry S, Fletcher AP, Alkjaersig N. Fibrinolysis and fibrinolytic activity in man. Physiol Rev. 1959;39:343-382.
3. Starzl TE, Marchioro TL, Von Kaulla KN, Hermann G, Brittain RS, Waddell WR. Homotransplantation of the liver in humans. Surg Gynecol Obstet. 1963;117:659-676.
4. Groth CG, Pechet L, Starzl TE. Coagulation during and after orthotopic transplantation of the human liver. Arch Surg. 1969;98:31-34.
5. Hardaway RM, Drake DC. Prevention of "irreversible" hemorrhagic shock with fibrinolysin. Ann Surg. 1963;157:39-47.
6. Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358:2319-2331.
7. Plotkin AJ, Wade CE, Jenkins DH, Smith KA, Noe JC, Park MS, Perkins JG, Holcomb JB. A reduction in clot formation rate and strength assessed by thrombelastography is indicative of transfusion requirements in patients with penetrating injuries. J Trauma. 2008;64(2 Supp):S64-S68.
8. Görlinger K, Dirkmann D, Solomon C, Hanke AA. Fast interpretation of thromboelastometry in non-cardiac surgery: reliability in patients with hypo-, normo-, and hypercoagulability. Br J Anaesth. 2013;110:222-230.
9. Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost. 2001;85:958-965.
10. Brohi K, Cohen MJ, Ganter MT, Matthay MA, Mackersie RC, Pittet JF. Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway? Ann Surg. 2007;245:812-818.
11. Brohi K, Cohen MJ, Ganter MT, Schultz MJ, Levi M, Mackersie RC, Pittet JF. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. J Trauma. 2008;64:1211-1217.
12. Kashuk JL, Moore EE, Sawyer M, Wohlauer M, Pezold M, Barnett C, Biffl WL, Burlew CC, Johnson JL, Sauaia A. Primary fibrinolysis is integral in the pathogenesis of the acute coagulopathy of trauma. Ann Surg. 2010;252:434-442.
13. Cotton BA, Harvin JA, Kostousouv V, Minei KM, Radwan ZA, Schöchl H, Wade CE, Holcomb JB, Matijevic N. Hyperfibrinolysis at admission is an uncommon but highly lethal event associated with shock and prehospital fluid administration. J Trauma Acute Care Surg. 2012;73:365-370.
14. Schöchl H, Frietsch T, Pavelka M, Jámbor C. Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry. J Trauma. 2009;67:125-131.
15. Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, et al, CRASH-2 collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomized, placebo-controlled trial. Lancet. 2010;376:23-32.
16. Napolitano LM, Cohen MJ, Cotton BA, Schreiber MA, Moore EE. Tranexamic acid in trauma: how should we use it? J Trauma Acute Care Surg. 2013;74:1575-1586.
17. Pusateri AE, Weiskopf RB, Bebarta V, Butler F, Cestero RF, Chaudry IH, Deal V, Dorlac WC, Gerhardt RT, Given MB, et al. Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities. Shock. 2013;39:121-126.
18. Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, et al, CRASH-2 collaborators. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011;377:1096-1101.
19. Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ. Military application of tranexamic acid in trauma emergency resuscitation (MATTERs) study. Arch Surg. 2012;147:113-119.
20. Valle EJ, Allen CJ, Van Haren RM, Jouria JM, Li H, Livingstone AS, Namias N, Schulman CI, Proctor KG. Do all trauma patients benefit from tranexamic acid? J Trauma Acute Care Surg. 2014;76:1373-1378.
21. Harvin JA, Mims MM, Hudson J, Podbielski J, Wade CE, Holcomb JB, Cotton BA. The impact of tranexamic acid on mortality in injured patients with hyperfibrinolysis. J Trauma Acute Care Surg. In press.
22. Chin TL, Moore EE, Moore HB, Gonzalez E, Chapman MP, Stringham JR, Ramos CR, Banerjee A, Sauaia A. A principal component analysis of postinjury viscoelastic assays: clotting factor depletion versus fibrinolysis. Surgery. 2014;156:570-577.
23. Kutcher ME, Ferguson AR, Cohen MJ. A principal component analysis of coagulation after trauma. J Trauma Acute Care Surg. 2013;74:1223-1229.
24. Moore HB, Moore EE, Gonzalez E, Chapman MP, Chin TL, Silliman CC, Banerjee A, Sauaia A. Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy. J Trauma Acute Care Surg. 2014;77: 811-817.
25. Moore HB, Moore EE, Lawson P, Gonzalez E, Fragoso M, Morton AP, Gamboni F, Chapman MP, Sauaia A, Banerjee A, et al. Fibrinolysis shutdown phenotype masks changes in rodent coagulation in tissue injury versus hemorrhagic shock. Surgery. In press.
26. Chapman MP, Moore EE, Ramos CR, Ghasabyan A, Harr JN, Chin TL, Stringham JR, Sauaia A, Silliman CC, Banerjee A. Fibrinolysis greater than 3% is the critical value for initiation of antifibrinolytic therapy. J Trauma Acute Care Surg. 2013;75:961-967.
27. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol. 2005;129:307-321.
28. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005;3:1894-1904.
29. Weisel JW. Structure of fibrin: impact on clot stability. J Thromb Haemost. 2007;5(SUPPL. 1):116-124.
30. Moore HB, Moore EE, Gonzalez E, Hansen KC, Dzieciatkowska M, Chapman MP, Sauaia A, West B, Banerjee A, Silliman CC. Hemolysis exacerbates hyperfibrinolysis while platelolysis shuts down fibrinolysis: evolving concepts of the spectrum of fibrinolysis in response to severe injury. Shock. 2015;43:39-46.
31. Moore HB, Moore EE, Gonzalez E, Chapman MP, Chin T, Banerjee A, Sauaia A, Silliman CC. Plasma is the physiologic buffer of tPA mediated fibrinolysis: rationale for plasma-first resuscitation after life-threatening hemorrhage. J Am Coll Surg. 2015;220(5):872-9.
32. Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor-1 (PAI-1) in plasma and platelets. Br J Haematol. 1988;70:327-333.
33. Gonzalez E, Moore EE, Moore HB, Pieracci FC, Chin T, Chapman MP, Sauaia A, Silliman CC, Banerjee A. Is fibrinolysis the missing link leading to postinjury hypercoagulability. J Am Coll Surg. 2014;219:s47.